Asia Pacific Human Albumin Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The Asia Pacific Human Albumin Market size is expected to reach US$ 1,643.3 Million by 2031 from US$ 962.2 Million in 2024. The market is estimated to record a CAGR of 8.1% from 2025 to 2031.

Executive Summary and Asia Pacific Human Albumin Market Analysis:

The Asia Pacific human albumin market is growing due to surging liver failure cases, record transplants, burn injuries, and critical care demands. In India, liver transplants reached 4,491 in 2023, per the National Organ & Tissue Transplant Organisation (NOTTO) under the Ministry of Health & Family Welfare. Total organ transplants hit a record 18,900 in 2024 (same source). Over 1 million moderate/severe burns occur annually, with 140,000 deaths (Directorate General of Health Services, 2017-18 report). In China, primary liver cancer incidence hit 367,700 new cases in 2022 (National Health Commission). 6,454 deceased donations supported transplants in 2023 (China Organ Transplant Response System). Central Drugs Standard Control Organisation (CDSCO) approved Phase III trials for recombinant Human Albumin 20% (Shilpa Medicare, 2024) and granted CT permissions, enhancing supply. Japan's liver waitlist stood at 560 patients.

Asia Pacific Human Albumin Market: Strategic Insights

Asia Pacific Human Albumin Market Segmentation Analysis:

• By Application, the Asia Pacific Human Albumin Market is segmented into Therapeutic Applications, Drug Delivery, Disease Diagnostics, Research, and Others. The Therapeutic Applications segment dominated the market in 2024.
• By Therapeutic Application, the Asia Pacific Human Albumin Market is segmented into Liver and Kidney Diseases, Surgery, Hypovolemia and Hypoalbuminemia, and Others. The Hypovolemia and Hypoalbuminemia segment dominated the market in 2024.
• By End User, the Asia Pacific Human Albumin Market is segmented into Hospitals and Clinics, Pharmaceutical and Biotechnological Companies, Research Institutes, Diagnostic Laboratories, Homecare Settings, and Others. The Hospitals and Clinics segment dominated the market in 2024.

Asia Pacific Human Albumin Market Players Density: Understanding Its Impact on Business Dynamics

The Asia Pacific Human Albumin Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Asia Pacific Human Albumin Market Outlook

In mid-2023, Kedrion Biopharma announced that China's National Institutes for Food and Drug Control (NIFDC) had approved BPL's human albumin product for release in the Chinese market, with launch commencing in April 2023. China is described as the "world's largest human albumin market" in that announcement. This regulatory milestone paves the way for increased penetration in populous markets. Also, product innovations such as packaging improvements (e.g., flexible bags, larger volumes) improve hospital logistics and may reduce infusion burdens. In December 2024, Grifols announced that its Phase 3 PRECIOSA trial in decompensated cirrhosis with ascites showed favorable results and reaffirmed safety for long-term human albumin therapy, potentially supporting label expansion. Emerging markets are witnessing a rising incidence of liver disease, kidney disease, trauma care, and critical care infrastructure development. The albumin therapy can capitalize on these trends. Regulatory access plus rising therapeutic demand in large populous countries thus constitutes a major opportunity for human albumin products.

Asia Pacific Human Albumin Market Country Insights

By country, the Asia Pacific Human Albumin Market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. China held the largest share in 2024.

According to the Chinese Ministry of Health, liver cirrhosis affected over 30 million individuals nationwide in 2022, with chronic liver disease cases surpassing 60 million, highlighting a substantial health burden. The incidence of acute kidney injury and nephrotic syndrome is rising, creating a higher demand for albumin-based treatments. Recent statistics from the National Health Commission indicate that hospital admissions related to liver and kidney conditions increased by approximately 15% in 2022 compared to the previous year. Advancements in product development, including the approval of highly purified and pathogen-inactivated albumin formulations by China's National Medical Products Administration (NMPA), have enhanced treatment safety and efficacy, encouraging wider adoption among healthcare providers. The government's initiatives to bolster plasma collection, such as the Plasma Donation Campaign, resulted in over 2 million liters of plasma collected in 2022, supporting local albumin production and reducing reliance on imports.

Asia Pacific Human Albumin Market Company Profiles

Some of the key players operating in the market include CSL Ltd, Biotest AG., Octapharma AG, Takeda Pharmaceutical Co Ltd, Merck KGaA, Grifols SA, Taibang Bio Group Co. Ltd., HiMedia Laboratories Pvt Ltd, Thermo Fisher Scientific Inc., and InVitria.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Asia Pacific Human Albumin Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note: All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise